Compounds > atrasentan
Page last updated: 2024-09-04

atrasentan and cabozantinib

atrasentan has been researched along with cabozantinib in 1 studies

Compound Research Comparison

Studies
(atrasentan)		Trials
(atrasentan)		Recent Studies (post-2010)
(atrasentan)		Studies
(cabozantinib)		Trials
(cabozantinib)		Recent Studies (post-2010) (cabozantinib)
35841108731127716

Protein Interaction Comparison

ProteinTaxonomyatrasentan (IC50)cabozantinib (IC50)
Epidermal growth factor receptorHomo sapiens (human)1.118
High affinity nerve growth factor receptorHomo sapiens (human)0.0723
Acyl-CoA desaturase 1Rattus norvegicus (Norway rat)0.0013
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.1699
Hepatocyte growth factor receptorHomo sapiens (human)0.0791
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0108
Fibroblast growth factor receptor 1Homo sapiens (human)0.0113
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.178
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.012
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.5617
Kinesin-1 heavy chainHomo sapiens (human)0.19
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.006
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.3151
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.8877
Angiopoietin-1 receptorHomo sapiens (human)0.0143
Macrophage-stimulating protein receptorHomo sapiens (human)0.069
Coiled-coil domain-containing protein 6Homo sapiens (human)0.4615
SAFB-like transcription modulatorHomo sapiens (human)0.0013

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ1

Reviews

1 review(s) available for atrasentan and cabozantinib

ArticleYear
Novel therapies for metastatic castrate-resistant prostate cancer.
    Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22

    Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays

2011